Company Filing History:
23 out of 3,384 
11 out of 13 
6 out of 6 
Years Active: 1994-2025
Title: H David Humes: Innovator in Cytopheresis and Myocardial Treatment
Introduction
H David Humes is a prominent inventor based in Ann Arbor, MI, known for his significant contributions to the field of medicine through his innovative patents. With a remarkable portfolio totaling 37 patents, Humes has focused primarily on advancements related to cytopheresis and myocardial function.
Latest Patents
Among his latest innovations, Humes has developed two notable patents:
1. **Cytopheresis Cartridges and Use Thereof** - This invention pertains to a cytopheretic cartridge designed to treat and prevent inflammatory conditions within subjects. The cartridge features a housing that encases a solid support capable of sequestering activated leukocytes and/or platelets.
2. **Cartridge and Method for Increasing Myocardial Function** - This patent relates to a cytopheretic cartridge aimed at addressing inflammatory conditions that affect myocardial function. It is particularly beneficial for treating subjects with myocardial dysfunction, including chronic heart failure and acute decompensated heart failure.
Career Highlights
David Humes has held key positions with prestigious organizations such as the University of Michigan and Cytopherx, Inc. His work in these institutions has been instrumental in the development and implementation of groundbreaking medical technologies.
Collaborations
Throughout his career, Humes has collaborated with esteemed colleagues including Deborah A Buffington and Christopher J Pino. These partnerships have facilitated the advancement of innovative solutions in medical treatments.
Conclusion
H David Humes stands out as a visionary inventor, continually pushing the boundaries of medical science through his inventions. His latest patents signify his commitment to improving health outcomes for individuals suffering from inflammatory and myocardial conditions. The impact of his work at institutions like the University of Michigan and Cytopherx, Inc. will likely be felt for years to come.